Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

1. Ability to provide written informed consent; 2. Previously enrolled in PRISM 3, had a CDI recurrence within 8 weeks of receiving CP101 or placebo, and have completed their PRISM 3 end of study visit; OR recurrent CDI 3. An outpatient prior to Treatment 4. Has received a course of standard-of-care CDI antibiotics for the most recent CDI episode, has had an adequate clinical response, and has completed a washout period. Exclusion Criteria: 1. Pregnant, breast-feeding, or considering becoming pregnant during the study 2. Prior history, evidence, or diagnosis of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis) 3. Any prior diagnosis of diarrhea-predominant irritable bowel syndrome 4. Systemic chemotherapy or radiation for the treatment of cancer during the 60 days prior to consent or planned during the 8 weeks following Randomization 5. Prior fecal transplant for any condition, regardless of route of administration in the last year or plans to undergo during the study 6. Major intra-abdominal surgery within the past 60 days prior to Screening 7. Admitted to, or expected to be admitted to an intensive care unit for any medical reason. Note: Residents of long term care facilities are eligible study entry 8. History of total colectomy/ileostomy or bariatric surgery 9. Planned hospitalization or invasive surgery during the study 10. Severe acute illness unrelated to CDI